Prevalence of measurable disease in metastatic castration resistant prostate cancer

• Published in: Clinical genitourinary cancer 2017-10, Vol.15 (5), p.534-539
• Main Authors: Sonpavde, G, Madan, A, Baker, M.K, May, J.E, Naik, G, Bae, S
• Format: Article
• Language: English
• Subjects: Castration-resistant; Clinical Trials as Topic; Hematology, Oncology and Palliative Medicine; Humans; Male; Measurable tumor; Metastatic; Neoplasm Metastasis; Prevalence; Prostate cancer; Prostate-Specific Antigen - metabolism; Prostatic Neoplasms, Castration-Resistant - diagnosis; Prostatic Neoplasms, Castration-Resistant - epidemiology; Prostatic Neoplasms, Castration-Resistant - metabolism; RECIST; Tomography, X-Ray Computed; Urology; Whole Body Imaging - methods
• ISSN: 1558-7673; 1938-0682
• DOI: 10.1016/j.clgc.2017.04.020

Abstract Background Given the low historical prevalence of measurable disease in metastatic castration-resistant prostate cancer (mCRPC), phase II trials have employed prostate specific antigen (PSA) and bone scan changes as primary endpoints. Frequent whole body imaging and improved computerized tomography technology currently identify measurable disease more frequently, warranting consideration of objective response as a major endpoint. Methods Data from reported phase III trials of mCRPC were analyzed. The proportion of patients with measurable disease, setting (pre-docetaxel [D], D-based, post-D), year of starting accrual, PSA, and the requirement for symptoms were collected. Chi-square test was used to evaluate the association of variables with measurable disease rate. Results Twenty phase III trials totaling 19,276 men with mCRPC were evaluable. Three trials (N=1289) started accruing before 2000 and 17 trials (N=17,987) accrued after 2000. The proportion of measurable disease rate for all trials was 47.5%. The measurable disease rate was significantly higher (p